Sökning: onr:"swepub:oai:DiVA.org:umu-57947" >
Lowering apolipopro...
Lowering apolipoprotein CIII delays onset of type 1 diabetes
-
Holmberg, Rebecka (författare)
-
- Refai, Essam (författare)
- Karolinska Institutet
-
- Höög, Anders (författare)
- Karolinska Institutet
-
visa fler...
-
Crooke, Rosanne M (författare)
-
Graham, Mark (författare)
-
- Olivecrona, Gunilla (författare)
- Umeå universitet,Fysiologisk kemi
-
- Berggren, Per-Olof (författare)
- Karolinska Institutet
-
- Juntti-Berggren, Lisa (författare)
- Karolinska Institutet
-
visa färre...
-
(creator_code:org_t)
- 2011-06-13
- 2011
- Engelska.
-
Ingår i: Proceedings of the National Academy of Sciences of the United States of America. - : National Academy of Sciences. - 0027-8424 .- 1091-6490. ; 108:26, s. 10685-10689
- Relaterad länk:
-
https://www.pnas.org...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Serum levels of apolipoprotein CIII (apoCIII) are increased in type 1 diabetic patients, and when β cells are exposed to these diabetic sera, apoptosis occurs, an effect abolished by an antibody against apoCIII. We have investigated the BB rat, an animal model that develops a human-like type 1 diabetes, and found that apoCIII was also increased in sera from prediabetic rats. This increase in apoCIII promoted β-cell death. The endogenous levels of apoCIII were reduced by treating prediabetic animals with an antisense against this apolipoprotein, resulting in a significantly delayed onset of diabetes. ApoCIII thus serves as a diabetogenic factor, and intervention with this apolipoprotein in the prediabetic state can arrest disease progression. These findings suggest apoCIII as a target for the treatment of type 1 diabetes.
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas